133 related articles for article (PubMed ID: 18227373)
1. Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis.
Shariat SF; Lamb DJ; Roehrborn CG; Slawin KM
Arch Intern Med; 2008 Jan; 168(2):235-6. PubMed ID: 18227373
[No Abstract] [Full Text] [Related]
2. Notice of duplicate publication: "Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis" (arch intern med. 2008;168[2]:235-236).
Shariat SF; Roehrborn CG; Lamb DJ; Slawin KM
Arch Intern Med; 2008 Oct; 168(18):2046-7. PubMed ID: 18852410
[No Abstract] [Full Text] [Related]
3. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
[TBL] [Abstract][Full Text] [Related]
4. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
5. Testosterone and prostate cancer.
Tubaro A
Eur Urol; 2007 Feb; 51(2):293-5. PubMed ID: 17034931
[No Abstract] [Full Text] [Related]
6. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
7. Testosterone supplementation and prostate cancer, controversies still exist.
Drewa T; Chłosta P
Acta Pol Pharm; 2010; 67(5):543-6. PubMed ID: 20873424
[TBL] [Abstract][Full Text] [Related]
8. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
9. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
[TBL] [Abstract][Full Text] [Related]
10. Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis.
Svatek RS; Shulman MJ; Benaim EA; Rogers TE; Margulis V
J Urol; 2008 Jun; 179(6):2192-5; discussion 2195-6. PubMed ID: 18423746
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
12. Variations in blood ghrelin levels in prostate cancer patients submitted to hormone suppressive treatment.
Bertaccini A; Pernetti R; Marchiori D; Pagotto U; Palladoro F; Palmieri F; Vitullo G; Guidi M; Martorana G
Anticancer Res; 2009 Apr; 29(4):1345-8. PubMed ID: 19414385
[TBL] [Abstract][Full Text] [Related]
13. Skin metastasis of prostate adenocarcinoma to glans penis showing no correlation with serum prostate-specific antigen level.
Kobashi-Katoh R; Tanioka M; Takahashi K; Miyachi Y
J Dermatol; 2009 Feb; 36(2):106-8. PubMed ID: 19284456
[No Abstract] [Full Text] [Related]
14. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Singh A
Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
[No Abstract] [Full Text] [Related]
15. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
16. Unusual prostate carcinoma characterized by extensive metastasis, significantly increased serum level of prostatic-specific antigen,and neuroendocrine differentiation: a case report.
Hu YX; Ye J; Jiang Y; Zhang QF; Wu YL; Chen YY
Chin Med J (Engl); 2005 Feb; 118(3):258-61. PubMed ID: 15740661
[No Abstract] [Full Text] [Related]
17. Are total prostate-specific antigen serum levels in cirrhotic men different from those in normal men?
Vicentini FC; Botelho LA; Hisano M; Ebaid GX; Lucon M; Lucon AM; Srougi M
Urology; 2009 May; 73(5):1032-5. PubMed ID: 19286245
[TBL] [Abstract][Full Text] [Related]
18. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer].
Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu
Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832
[TBL] [Abstract][Full Text] [Related]
19. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.
Van Patten CL; de Boer JG; Tomlinson Guns ES
J Urol; 2008 Dec; 180(6):2314-21; discussion 2721-2. PubMed ID: 18930254
[TBL] [Abstract][Full Text] [Related]
20. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
